A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial
Gerardo Rosati(Ospedale San Carlo), Roberto Labianca(Ospedale Papa Giovanni XXIII), A. Ciarlo, Ilaria Bernardini(University of Siena), Rossana Casaretti(Tumour Institute of Tuscany), Stefania Mosconi(Ospedale Papa Giovanni XXIII), Stefano Cascinu(Vita-Salute San Raffaele University), Michele Prisciandaro(Fondazione IRCCS Istituto Nazionale dei Tumori), Federica Zoratto(Ospedale Santa Maria Goretti), Sandro Barni, Giovanna Luchena(Ospedale Sant'Anna), Luigi Cavanna(University of Pavia), Carla Codecà(Ospedale San Paolo), Chiara Alessandra Cella(European Institute of Oncology), Cristina Davite(Nerviano Medical Sciences), Nicola Silvestris(University of Messina), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Alessia Casolaro(Nerviano Medical Sciences), D. Amoroso(Ospedale Versilia), Alessandro Di Sanzo(Nerviano Medical Sciences)
Cited by 4
Related Papers
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k